The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 05, 2024

Filed:

Jan. 16, 2019
Applicant:

Syros Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Jason J. Marineau, Franklin, MA (US);

Claudio Edmundo Chuaqui, Arlington, MA (US);

Stephane Ciblat, Montreal, CA;

Anzhelika Kabro, Montreal, CA;

Henri Piras, Montreal, CA;

Kenneth Matthew Whitmore, Montreal, CA;

Kate-Lyn Lund, Lachine, CA;

Michael Bradley, Houston, TX (US);

Assignee:

Syros Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 413/14 (2006.01); A61P 35/00 (2006.01); A61K 31/675 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01); C07D 487/08 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/08 (2013.01); C07F 9/65583 (2013.01);
Abstract

The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).


Find Patent Forward Citations

Loading…